Two new studies further question Avandia safety

Share this article:

Two new studies have once again called into question the safety of GlaxoSmithKline's type 2 diabetes drug Avandia.

Both studies were published Sept. 11 in the Journal of the American Medical Association (JAMA).

One of the new studies, a meta-analysis co-authored by Dr. Steven Nissen of the Cleveland Clinic, found that Avandia rival drug, Takeda's Actos, appeared to protect patients from heart attacks, stroke and death by 18%. It was also Nissen who first published results of a meta-analysis in the New England Journal of Medicine in May that linked the Avandia to an increased risk of heart attack.

GSK has defended Avandia's safety with data from its own clinical trials and criticized Nissen's May meta-analysis methodology, which combined the results from different studies. 

The second of the two new studies published in JAMA backs up Nissen's earlier findings on Avandia. The second study, also a meta-analysis, was conducted by a team from Wake Forest University. The Wake Forest team found the Avandia increased the risk of heart attack by 42%. Nissen's earlier survey found a 43% increased risk.

GSK said in a statement posted on their Web site that the conclusions of the JAMA studies “do not confirm a difference in the safety profile of Avandia (rosiglitazone) and Actos (pioglitazone).” The statement added that the studies “do not yield data robust enough to guide doctors in selecting appropriate diabetes treatments for their patients.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...